Sara Margolin Swedish researcher
Margolin, Sara, 1965-
VIAF ID: 19660043 (Personal)
Permalink: http://viaf.org/viaf/19660043
Preferred Forms
- 100 1 _ ‡a Margolin, Sara ‡d 1965-
- 100 1 _ ‡a Margolin, Sara, ‡d 1965-
- 100 0 _ ‡a Sara Margolin ‡c Swedish researcher
4xx's: Alternate Name Forms (4)
Works
Title | Sources |
---|---|
The BRCA2 c.68-7T > A variant is not pathogenic: A model for clinical calibration of spliceogenicity. | |
BRCA2 Hypomorphic Missense Variants Confer Moderate Risks of Breast Cancer | |
BRCA2 Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian Cancers | |
Breast cancer risk variants at 6q25 display different phenotype associations and regulate ESR1, RMND1 and CCDC170. | |
CHEK2 1100delC is prevalent in Swedish early onset familial breast cancer | |
Combined genetic and splicing analysis of BRCA1 c.[594-2A>C; 641A>G] highlights the relevance of naturally occurring in-frame transcripts for developing disease gene variant classification algorithms | |
Correction: Comparison of 6q25 Breast Cancer Hits from Asian and European Genome Wide Association Studies in the Breast Cancer Association Consortium (BCAC) | |
DNA mismatch repair gene MSH6 implicated in determining age at natural menopause | |
The estrogen receptor alpha C975G variant in familial and sporadic breast cancer: a case-control study. | |
Evaluation of variation in the phosphoinositide-3-kinase catalytic subunit alpha oncogene and breast cancer risk | |
Evidence that the 5p12 Variant rs10941679 Confers Susceptibility to Estrogen-Receptor-Positive Breast Cancer through FGF10 and MRPS30 Regulation | |
Familial breast cancer, underlying genes, and clinical implications: a review | |
Family history and breast cancer susceptibility : clinical and molecular studies | |
The FANCM:p.Arg658* truncating variant is associated with risk of triple-negative breast cancer | |
Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes | |
Fine scale mapping of the 17q22 breast cancer locus using dense SNPs, genotyped within the Collaborative Oncological Gene-Environment Study (COGs). | |
Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus | |
Genetic modifiers of CHEK2*1100delC-associated breast cancer risk | |
Genetic predisposition to in situ and invasive lobular carcinoma of the breast | |
Genetic variation in mitotic regulatory pathway genes is associated with breast tumor grade | |
Genetically Predicted Body Mass Index and Breast Cancer Risk: Mendelian Randomization Analyses of Data from 145,000 Women of European Descent | |
Genome-wide association analysis of more than 120,000 individuals identifies 15 new susceptibility loci for breast cancer | |
Identification of a BRCA2-specific modifier locus at 6p24 related to breast cancer risk | |
Identification of independent association signals and putative functional variants for breast cancer risk through fine-scale mapping of the 12p11 locus | |
Identification of novel genetic markers of breast cancer survival | |
Incorporating progesterone receptor expression into the PREDICT breast prognostic model | |
An intergenic risk locus containing an enhancer deletion in 2q35 modulates breast cancer risk by deregulating IGFBP5 expression | |
Large-Scale Genomic Analyses Link Reproductive Aging to Hypothalamic Signaling, Breast Cancer Susceptibility, and BRCA1-Mediated DNA Repair | |
Large-scale genotyping identifies 41 new loci associated with breast cancer risk | |
Long-term safety and survival outcomes from the Scandinavian Breast Group 2004-1 randomized phase II trial of tailored dose-dense adjuvant chemotherapy for early breast cancer. | |
Mendelian randomisation study of smoking exposure in relation to breast cancer risk | |
Missense variants in ATM in 26,101 breast cancer cases and 29,842 controls | |
Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer | |
A network analysis to identify mediators of germline-driven differences in breast cancer prognosis | |
A new polymorphism in the coding region of exon four in HSD17B2 in relation to risk of sporadic and hereditary breast cancer | |
No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. | |
PALB2, CHEK2 and ATM rare variants and cancer risk: data from COGS | |
Parent of Origin and Prognosis in Familial Breast Cancer in Sweden | |
Patient survival and tumor characteristics associated with CHEK2:p.I157T - findings from the Breast Cancer Association Consortium | |
PHIP - a novel candidate breast cancer susceptibility locus on 6q14.1. | |
Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes | |
Polymorphisms in a Putative Enhancer at the 10q21.2 Breast Cancer Risk Locus Regulate NRBF2 Expression | |
Prediction of breast cancer risk based on profiling with common genetic variants | |
Publisher Correction: Evidence that breast cancer risk at the 2q35 locus is mediated through IGFBP5 regulation. | |
Refined histopathological predictors of BRCA1 and BRCA2 mutation status: a large-scale analysis of breast cancer characteristics from the BCAC, CIMBA, and ENIGMA consortia | |
Reproductive profiles and risk of breast cancer subtypes: a multi-center case-only study. | |
A retrospective safety and efficacy analysis of the first patients treated with eribulin for metastatic breast cancer in Stockholm, Sweden | |
The role of genetic breast cancer susceptibility variants as prognostic factors | |
Shared heritability and functional enrichment across six solid cancers | |
The SNP rs6500843 in 16p13.3 is associated with survival specifically among chemotherapy-treated breast cancer patients | |
SNP-SNP interaction analysis of NF-κB signaling pathway on breast cancer survival | |
TP53-based interaction analysis identifies cis-eQTL variants for TP53BP2, FBXO28, and FAM53A that associate with survival and treatment outcome in breast cancer | |
Transcriptome-wide association study of breast cancer risk by estrogen-receptor status | |
Treatment Restarting After Discontinuation of Adjuvant Hormone Therapy in Breast Cancer Patients | |
Tumour spectrum in non-BRCA hereditary breast cancer families in Sweden |